1. Pink Sheet
  2. >>Geography
  3. >>Europe

EMA Updates GCP Guide To Clarify Sponsor Role In Contracting For Trial-Related Tasks

 
• By Vibha Sharma

Based on the trial design and setting, the European Medicines Agency says the sponsor may support the investigator by identifying or contracting service providers or personnel to be involved directly in the conduct of the clinical trial.

African doctor wear headset consult female black patient make online webcam video call on laptop screen. Telemedicine videoconference remote computer app virtual meeting. Over shoulder videocall view.
The investigator is ultimately responsible for any tasks involving trial-related medical decisions • Source: Shutterstock

The European Medicines Agency has updated its good clinical practice (GCP) guidance to support changing trends in the conduct of clinical trials, such as the increasing tendency of sponsors of decentralized clinical trials (DCTs) to get involved in contracting service providers for tasks that traditionally fall within the remit of the trial investigator.

The GCP Q&A has also been updated to address the use of productivity software in clinical trials, for example, to...

Welcome to Pink Sheet

Create an account to read this article

Already a subscriber?

More from Europe

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three

 
• By Eliza Slawther and Neena Brizmohun

The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.

Lilly Wins EU Thumbs Up For Kisunla After EMA Reverses Rejection

 
• By Neena Brizmohun

The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.

EMA Says ‘No’ To Roche/Sarepta’s Elevidys, US FDA Investigates Fourth Death

 
• By Eliza Slawther and Sarah Karlin-Smith

The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.

EU’s Life Sciences Strategy Faces Race Against Time, Says Clinical Trials Community

 
• By Vibha Sharma

The report gave examples of missed opportunities for innovation and patient access, as well as regulatory and operational problems that undermine the conduct of timely clinical trials in Europe.

More from Geography

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three

 
• By Eliza Slawther and Neena Brizmohun

The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.

Lilly Wins EU Thumbs Up For Kisunla After EMA Reverses Rejection

 
• By Neena Brizmohun

The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.

EMA Says ‘No’ To Roche/Sarepta’s Elevidys, US FDA Investigates Fourth Death

 
• By Eliza Slawther and Sarah Karlin-Smith

The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.